Cargando…

A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients

BACKGROUND: The objective of this paper is to explore the value of a delta-radiomic model of the axillary lymph node (ALN) using dynamic contrast-enhanced (DCE) MRI for early prediction of the axillary pathological complete response (pCR) of breast cancer patients after neoadjuvant chemotherapy (NAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shasha, Du, Siyao, Gao, Si, Teng, Yuee, Jin, Feng, Zhang, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817310/
https://www.ncbi.nlm.nih.gov/pubmed/36604679
http://dx.doi.org/10.1186/s12885-022-10496-5
_version_ 1784864727238705152
author Liu, Shasha
Du, Siyao
Gao, Si
Teng, Yuee
Jin, Feng
Zhang, Lina
author_facet Liu, Shasha
Du, Siyao
Gao, Si
Teng, Yuee
Jin, Feng
Zhang, Lina
author_sort Liu, Shasha
collection PubMed
description BACKGROUND: The objective of this paper is to explore the value of a delta-radiomic model of the axillary lymph node (ALN) using dynamic contrast-enhanced (DCE) MRI for early prediction of the axillary pathological complete response (pCR) of breast cancer patients after neoadjuvant chemotherapy (NAC). METHODS: A total of 120 patients with ALN-positive breast cancer who underwent breast MRI before and after the first cycle of NAC between October 2018 and May 2021 were prospectively included in this study. Patients were divided into a training (n = 84) and validation (n = 36) cohort based on the temporal order of their treatments. Radiomic features were extracted from the largest slice of targeted ALN on DCE-MRI at pretreatment and after one cycle of NAC, and their changes (delta-) were calculated and recorded. Logistic regression was then applied to build radiomic models using the pretreatment (pre-), first-cycle(1st-), and changes (delta-) radiomic features separately. A clinical model was also built and combined with the radiomic models. The models were evaluated by discrimination, calibration, and clinical application and compared using DeLong test. RESULTS: Among the three radiomic models, the ALN delta-radiomic model performed the best with AUCs of 0.851 (95% CI: 0.770–0.932) and 0.822 (95% CI: 0.685–0.958) in the training and validation cohorts, respectively. The clinical model yielded moderate AUCs of 0.742 (95% CI: 0.637–0.846) and 0.723 (95% CI: 0.550–0.896), respectively. After combining clinical features to the delta-radiomics model, the efficacy of the combined model (AUC = 0.932) in the training cohort was significantly higher than that of both the delta-radiomic model (Delong p = 0.017) and the clinical model (Delong p < 0.001) individually. Additionally, in the validation cohort, the combined model had the highest AUC (0.859) of any of the models we tested although this was not statistically different from any other individual model’s validation AUC. Calibration and decision curves showed a good agreement and a high clinical benefit for the combined model. CONCLUSION: This preliminary study indicates that ALN-based delta-radiomic model combined with clinical features is a promising strategy for the early prediction of downstaging ALN status after NAC. Future axillary MRI applications need to be further explored. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10496-5.
format Online
Article
Text
id pubmed-9817310
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98173102023-01-07 A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients Liu, Shasha Du, Siyao Gao, Si Teng, Yuee Jin, Feng Zhang, Lina BMC Cancer Research BACKGROUND: The objective of this paper is to explore the value of a delta-radiomic model of the axillary lymph node (ALN) using dynamic contrast-enhanced (DCE) MRI for early prediction of the axillary pathological complete response (pCR) of breast cancer patients after neoadjuvant chemotherapy (NAC). METHODS: A total of 120 patients with ALN-positive breast cancer who underwent breast MRI before and after the first cycle of NAC between October 2018 and May 2021 were prospectively included in this study. Patients were divided into a training (n = 84) and validation (n = 36) cohort based on the temporal order of their treatments. Radiomic features were extracted from the largest slice of targeted ALN on DCE-MRI at pretreatment and after one cycle of NAC, and their changes (delta-) were calculated and recorded. Logistic regression was then applied to build radiomic models using the pretreatment (pre-), first-cycle(1st-), and changes (delta-) radiomic features separately. A clinical model was also built and combined with the radiomic models. The models were evaluated by discrimination, calibration, and clinical application and compared using DeLong test. RESULTS: Among the three radiomic models, the ALN delta-radiomic model performed the best with AUCs of 0.851 (95% CI: 0.770–0.932) and 0.822 (95% CI: 0.685–0.958) in the training and validation cohorts, respectively. The clinical model yielded moderate AUCs of 0.742 (95% CI: 0.637–0.846) and 0.723 (95% CI: 0.550–0.896), respectively. After combining clinical features to the delta-radiomics model, the efficacy of the combined model (AUC = 0.932) in the training cohort was significantly higher than that of both the delta-radiomic model (Delong p = 0.017) and the clinical model (Delong p < 0.001) individually. Additionally, in the validation cohort, the combined model had the highest AUC (0.859) of any of the models we tested although this was not statistically different from any other individual model’s validation AUC. Calibration and decision curves showed a good agreement and a high clinical benefit for the combined model. CONCLUSION: This preliminary study indicates that ALN-based delta-radiomic model combined with clinical features is a promising strategy for the early prediction of downstaging ALN status after NAC. Future axillary MRI applications need to be further explored. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10496-5. BioMed Central 2023-01-05 /pmc/articles/PMC9817310/ /pubmed/36604679 http://dx.doi.org/10.1186/s12885-022-10496-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Shasha
Du, Siyao
Gao, Si
Teng, Yuee
Jin, Feng
Zhang, Lina
A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients
title A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients
title_full A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients
title_fullStr A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients
title_full_unstemmed A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients
title_short A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients
title_sort delta-radiomic lymph node model using dynamic contrast enhanced mri for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817310/
https://www.ncbi.nlm.nih.gov/pubmed/36604679
http://dx.doi.org/10.1186/s12885-022-10496-5
work_keys_str_mv AT liushasha adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT dusiyao adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT gaosi adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT tengyuee adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT jinfeng adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT zhanglina adeltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT liushasha deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT dusiyao deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT gaosi deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT tengyuee deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT jinfeng deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients
AT zhanglina deltaradiomiclymphnodemodelusingdynamiccontrastenhancedmrifortheearlypredictionofaxillaryresponseafterneoadjuvantchemotherapyinbreastcancerpatients